Anti-Human IL 12/23 (Briakinumab) Dylight® 488

Price

2,230.00 ₪

Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23.

IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23.

IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions.

In addition, IL-23 is suspected to play a role in tumorigenesis.

Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

Package Size

Quantity

Storage and Stability

This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Formulation

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Shipping Conditions

Next Day 2-8°C